Redesign Health and ARC Global Merge to Help Health Systems Shape the Future of Healthcare From Within
Redesign Health and Sheba Medical Center’s ARC Global also to acquire AVIA, with the three organizations bringing together…
Launch price of new medicines dropped very slightly in 2025
Amid ongoing angst over prescription drug prices, a new analysis found the median net price for 202 newly…
New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one year
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a…
Supplement sector rising, ‘safety needs to evolve with it’
Speaking during a webinar hosted by the International Alliance of Dietary and Food Supplement Associations (IADSA) last week,…
UnitedHealth Group (UNH) earnings Q3 2026
UnitedHealth Group signage on the floor of the New York Stock Exchange on April 21, 2025. Michael Nagle…
USFDA’s gummy study, Australia’s rules on andrographis in regulatory round-up
The mature dietary supplement market has been drawing increasing scrutiny from regulators, inspectors and legacy supplement brands. (Colorsandia…
Taxpayers shouldn’t pay for an ineffective multi-cancer screening test
There must be some mistake. A company studies its cancer blood test in a randomized trial of 140,000…
Probing the many benefits of GLP-1 receptor agonists
RESEARCH HIGHLIGHT 05 October 2026 Glucagon-like peptide 1 (GLP-1) receptor agonists are approved for the treatment of type…
AstraZeneca CEO says Summit drug could drive future cancer combos
AstraZeneca CEO Pascal Soriot told CNBC on Monday that Summit Therapeutics‘ lead drug could help power next-generation cancer…
Eli Lilly, NIH grants, Novartis, Regeneron: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV
Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today announced…
Eli Lilly obesity drug with amylin, tirzepatide boosts weight loss in trial
Eli Lilly on Wednesday said its experimental combination regimen resulted in greater weight loss than a high dose…